In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole

Drug Metabolism and Disposition

Volumn 25, Issue 7, 1997, Pages 840-844

  Bloomer, J C ^a   Clarke, S E ^b   Chenery, R J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ROPINIROLE;

ARTICLE; BINDING AFFINITY; BIOTRANSFORMATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DOPAMINE AGONISTS; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; INDOLES; ISOENZYMES; MICROSOMES, LIVER; MULTIVARIATE ANALYSIS;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0030753786     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. R. J. Eden, B. Costall, A. M. Domeney, P. A. Gerrard, C. A. Harvey, M. E. Kelly, R. J. Naylor, D. A. Owen, and A. Wright: Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav. 38, 147-54 (1991).
2. P. K. Smith, R. L. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and C. Klenk: Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85 (1985).
3. D. Sesardic, A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. De La Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
4. S. E. Clarke, A. D. Ayrton, and R. J. Chenery: Characterisation of the inhibition of cytochrome P4501A2 by furafylline. Xenobiotica 24, 517-526 (1994).
5. J. O. Miners, K. J. Smith, R. A. Robson, M. E. McManus, M. E. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes, kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37, 1137-1144 (1988).
6. M. E. Veronese, C. J. Doecke, P. I. MacKenzie, M. E. McManus, J. O. Miners, D. L. P. Rees, R. Gasser, U. A. Meyer, and D. J. Birkett: Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem. J. 289, 533-538 (1993).
7. S. V. Otton, H. K. Crewe, M. S. Lennard, G. T. Tucker, and H. F. Woods: Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247, 242-247 (1988).
8. M. Maurice, L. Pichard, M. Daujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6, 752-758 (1992).
9. S. J. Baldwin, J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261-270 (1995).
10. F. Berthou, J.-P. Flinois, D. Ratanasavanh, P. Beaune, C. Riche, and A. Guillouzo: Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab. Dispos. 19, 561-567 (1991).
11. M. E. Campbell, D. M. Grant, T. Inaba, and W. Kalow: Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab. Dispos. 15, 237-249 (1987).
12. S. Yamano, J. Tatsuno, and F. J. Gonzalez: The CYP2A3 gene product catalyzes coumarin N-despropylation in human liver microsomes. Biochem. 29, 1322-1329 (1990).
13. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. Vandenbranden: Isolation and characterisation of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′ hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
14. U. M. Zanger, F. Vilbois, J. E. Hardwick, and U. A. Meyer: Absence of hepatic cytochrome P450buf1 causes genetically deficient debrisoquine oxidation in man. Biochem. 27, 5447-5454 (1988).
15. R. Peter, R. Böcker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
16. D. J. Waxman, D. P. Lapenson, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and K. Korzekwa: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290, 160-166 (1991).
17. H. A. A. M. Dirven, J. G. P. Peters, G. G. Gibson, W. H. M. Peters, and F. J. Jongeneelen: Lauric acid hydroxylase activity and cytochrome P450 IV family proteins in human liver microsomes. Biochem. Pharmacol. 42, 1841-1844 (1991).
18. M. D. Burke, S. Thompson, C. R. Elcombe, J. Halpert, T. Haaparanta, and R. T. Mayer: Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34, 3337-3345 (1985).
19. M. Maurice, S. Emiliani, I. Dalet-Beluche, J. Derancourt, and R. Lange: Isolation and characterisation of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur. J. Biochem. 200, 511-517 (1991).
20. J. C. Bloomer, S. J. Baldwin, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br. J. Clin. Pharmacol. 38, 557-566 (1994).
21. R. J. Leatherbarrow: Grafit, Version 3.0, Erithacus Software Ltd., Staines, UK (1992).
22. SAS/INSIGHT® Users Guide, Version 6, 2nd Ed., SAS Institute Inc., Cary, NC (1993).
23. N. R. Draper and H. Smith: Applied Regression Analysis, 2nd Ed. Wiley, New York (1980).
24. B. R. Boothman and E. G. S. Spokes: Pharmacokinetic data for ropinirole. Lancet 336, 814 (1990).
25. U. Fuhr, E. M. Anders, G. Mahr, F. Sorgel, and A. H. Staib: Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob. Agents Chemother. 36, 942-948 (1992).
26. K. Brosen, E. Skjelbo, B. B. Rasmussen, H. E. Poulson, and S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45, 1211-1214 (1992).
27. A. C. Taylor, M. Cyronak, D. R. Citerone, K. Fitzpatrick, S. Cooper, A. Lopez-Gil, and O. Rascol: Lack of a pharmacokinetic interaction between ropinirole and theophylline in Parkinsonian patients. Br. J. Clin. Pharmacol. 43, 555P-556P.